CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Rain Oncology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Rain Oncology Inc
8000 Jarvis Avenue, Suite 204
Phone: (510) 953-5559p:510 953-5559 NEWARK, CA  94560  United States
This company was Merged or Acquired on 1/26/2024.
This company ceased filing statements with the SEC on 2/5/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Rain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan. Milademetan is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53. The product candidate is being developed in patients with MDM2-dependent cancers. p53 acts as a regulator of various cellular processes. The activity of p53 is controlled and regulated by the inhibitory protein MDM2. MDM2 binds to p53, thereby inducing degradation and allowing normal cells to function properly. Milademetan, by binding MDM2 at the p53 interaction site, prevents the formation of the MDM2-p53 complex, allowing p53 reactivation and subsequent transcription of genes that trigger cancer cell cycle arrest or apoptosis and can be readily measured by increases in the pharmacodynamic marker MIC-1 (GDF15) in the blood.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Co-Founder AvanishVellanki 48 4/1/2021 4/1/2017
President, Co-Founder, Chief Scientific Officer Chief Medical Officer RobertDoebele 52 6/1/2023 9/1/2020
Principal Financial Officer, Principal Accounting Officer JoyBruce 44 6/1/2023 6/1/2023
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 63 (As of 12/31/2022)
Outstanding Shares: 36,384,709 (As of 12/11/2023)
Shareholders: 27
Stock Exchange: NASD
Federal Tax Id: 821130967


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 21, 2024